07:00 , May 16, 2011 |  BC Week In Review  |  Clinical News

Accolate zafirlukast inflammation data

Researchers from the University of Aberdeen reported data from 2 open-label pragmatic trials showing that leukotriene antagonists Singular and Accolate produced equivalent increases in MiniAQLQ scores vs. inhaled corticosteroid controller medication (ICS) as first-line therapy...